Lipoproteins and Cardiovascular Disease: An Update on the Clinical Significance of Atherogenic Small, Dense LDL and New Therapeutical Options

Dyslipidemia is a potent risk factor for the genesis and progression of cardiovascular disease (CVD), and both the concentration and type of low-density lipoproteins (LDL) augment this association. The small, dense LDL (sdLDL) subfraction is the subtype which is most strongly predictive of atheroscl...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ali A. Rizvi, Anca Pantea Stoian, Andrej Janez, Manfredi Rizzo
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	small dense LDL prevention cardiovascular risk therapy diabetes Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/239a0fd9ed42401d81fc6c024719ad16
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:239a0fd9ed42401d81fc6c024719ad16
record_format	dspace
spelling	oai:doaj.org-article:239a0fd9ed42401d81fc6c024719ad162021-11-25T16:49:12ZLipoproteins and Cardiovascular Disease: An Update on the Clinical Significance of Atherogenic Small, Dense LDL and New Therapeutical Options10.3390/biomedicines91115792227-9059https://doaj.org/article/239a0fd9ed42401d81fc6c024719ad162021-10-01T00:00:00Zhttps://www.mdpi.com/2227-9059/9/11/1579https://doaj.org/toc/2227-9059Dyslipidemia is a potent risk factor for the genesis and progression of cardiovascular disease (CVD), and both the concentration and type of low-density lipoproteins (LDL) augment this association. The small, dense LDL (sdLDL) subfraction is the subtype which is most strongly predictive of atherosclerosis and cardiovascular events. In addition to the traditionally available lipid-lowering treatment options, certain novel therapies have been shown to favorably impact sdLDL, among them the antidiabetic class of agents known as glucagon-like peptide 1 receptor agonists (GLP1-RAs). These drugs seem to alter the pathophysiologic mechanisms responsible for the formation and accumulation of atherogenic lipoprotein particles, thus potentially reducing cardiovascular outcomes. They represent a uniquely targeted therapeutic approach to reduce cardiometabolic risk and warrant further study for their beneficial nonglycemic actions.Ali A. RizviAnca Pantea StoianAndrej JanezManfredi RizzoMDPI AGarticlesmalldense LDLpreventioncardiovascular risktherapydiabetesBiology (General)QH301-705.5ENBiomedicines, Vol 9, Iss 1579, p 1579 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	small dense LDL prevention cardiovascular risk therapy diabetes Biology (General) QH301-705.5
spellingShingle	small dense LDL prevention cardiovascular risk therapy diabetes Biology (General) QH301-705.5 Ali A. Rizvi Anca Pantea Stoian Andrej Janez Manfredi Rizzo Lipoproteins and Cardiovascular Disease: An Update on the Clinical Significance of Atherogenic Small, Dense LDL and New Therapeutical Options
description	Dyslipidemia is a potent risk factor for the genesis and progression of cardiovascular disease (CVD), and both the concentration and type of low-density lipoproteins (LDL) augment this association. The small, dense LDL (sdLDL) subfraction is the subtype which is most strongly predictive of atherosclerosis and cardiovascular events. In addition to the traditionally available lipid-lowering treatment options, certain novel therapies have been shown to favorably impact sdLDL, among them the antidiabetic class of agents known as glucagon-like peptide 1 receptor agonists (GLP1-RAs). These drugs seem to alter the pathophysiologic mechanisms responsible for the formation and accumulation of atherogenic lipoprotein particles, thus potentially reducing cardiovascular outcomes. They represent a uniquely targeted therapeutic approach to reduce cardiometabolic risk and warrant further study for their beneficial nonglycemic actions.
format	article
author	Ali A. Rizvi Anca Pantea Stoian Andrej Janez Manfredi Rizzo
author_facet	Ali A. Rizvi Anca Pantea Stoian Andrej Janez Manfredi Rizzo
author_sort	Ali A. Rizvi
title	Lipoproteins and Cardiovascular Disease: An Update on the Clinical Significance of Atherogenic Small, Dense LDL and New Therapeutical Options
title_short	Lipoproteins and Cardiovascular Disease: An Update on the Clinical Significance of Atherogenic Small, Dense LDL and New Therapeutical Options
title_full	Lipoproteins and Cardiovascular Disease: An Update on the Clinical Significance of Atherogenic Small, Dense LDL and New Therapeutical Options
title_fullStr	Lipoproteins and Cardiovascular Disease: An Update on the Clinical Significance of Atherogenic Small, Dense LDL and New Therapeutical Options
title_full_unstemmed	Lipoproteins and Cardiovascular Disease: An Update on the Clinical Significance of Atherogenic Small, Dense LDL and New Therapeutical Options
title_sort	lipoproteins and cardiovascular disease: an update on the clinical significance of atherogenic small, dense ldl and new therapeutical options
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/239a0fd9ed42401d81fc6c024719ad16
work_keys_str_mv	AT aliarizvi lipoproteinsandcardiovasculardiseaseanupdateontheclinicalsignificanceofatherogenicsmalldenseldlandnewtherapeuticaloptions AT ancapanteastoian lipoproteinsandcardiovasculardiseaseanupdateontheclinicalsignificanceofatherogenicsmalldenseldlandnewtherapeuticaloptions AT andrejjanez lipoproteinsandcardiovasculardiseaseanupdateontheclinicalsignificanceofatherogenicsmalldenseldlandnewtherapeuticaloptions AT manfredirizzo lipoproteinsandcardiovasculardiseaseanupdateontheclinicalsignificanceofatherogenicsmalldenseldlandnewtherapeuticaloptions
_version_	1718412943827140608

Lipoproteins and Cardiovascular Disease: An Update on the Clinical Significance of Atherogenic Small, Dense LDL and New Therapeutical Options

Ejemplares similares